| Authors: |
Mitchell JM; Neuroscape, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. jennifer.mitchell@ucsf.edu.; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA, USA. jennifer.mitchell@ucsf.edu.; Department of Veterans Affairs, Research Service, San Francisco VA Medical Center, San Francisco, CA, USA. jennifer.mitchell@ucsf.edu., Ot'alora G M; Aguazul-Bluewater, Inc, Boulder, CO, USA., van der Kolk B; Boston University School of Medicine, Boston, MA, USA., Shannon S; Wholeness Center, Fort Collins, CO, USA., Bogenschutz M; Department of Psychiatry, New York University Grossman School of Medicine, New York, NY, USA., Gelfand Y; Zen Therapeutic Solutions, Mt. Pleasant, SC, USA., Paleos C; Nautilus Sanctuary, New York, NY, USA., Nicholas CR; Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Quevedo S; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA, USA.; San Francisco Insight and Integration Center, San Francisco, CA, USA., Balliett B; New School Research, LLC, Los Angeles, CA, USA., Hamilton S; MAPS Public Benefit Corporation, San Jose, CA, USA., Mithoefer M; Medical University of South Carolina, Charleston, SC, USA., Kleiman S; Kleiman Consulting and Psychological Services, PC, Ivyland, PA, USA., Parker-Guilbert K; KPG Psychological Services, LLC, Brunswick, ME, USA., Tzarfaty K; University of Haifa, Haifa, Israel.; MAPS Israel, Hod Hasharon, Israel., Harrison C; MAPS Public Benefit Corporation, San Jose, CA, USA., de Boer A; Tulip Medical Consulting, LLC, Port Townsend, WA, USA., Doblin R; Multidisciplinary Association for Psychedelic Studies (MAPS), San Jose, CA, USA., Yazar-Klosinski B; MAPS Public Benefit Corporation, San Jose, CA, USA. |
